Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,064.01
(
-0.63%
)
US TECH 100
25,960.80
(
0.73%
)
Dow Jones
49,149.38
(
-0.60%
)
Brent Oil
94.97
(
-0.05%
)
Bitcoin
78,235.93
(
2.50%
)
News Focus
News Focus
Post# of 447426
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

ziploc_1

Send PM Follow Ignore
Followers 64
Posts 7751
Boards Moderated 1
Alias Born 01/02/2003

ziploc_1

Re: Tatsumaki post# 418548

Sunday, 12/03/2023 5:20:37 PM

Sunday, December 03, 2023 5:20:37 PM

Post# of 447426
Tats...QUOTE..."Cost and side effects will not stop GLP-1 drugs from absolutely destroying V sales in the AD space"...

You must be kidding...Cost and Side effects always matter a great deal....Also, having AD stokes much more fear in patients than the fear of being overweight or diabetic.....I know because I have both relatives in my family, who are diabetic and overweight plus relatives, who have Alzheimers.

Diabetes and overweight are a nuisance...Alzheimers is a curse.

Incidentally, Diabetes and overweight are factors known to induce CVD...Vascepa has been proven to help with those also.
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News